Welcome to our dedicated page for APIMEDS PHARMACEUTICALS US SEC filings (Ticker: APUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) provides access to the company’s regulatory disclosures as an Exchange Act registrant with common stock listed on the NYSE American. These filings document key aspects of Apimeds’ evolution as a clinical-stage biopharmaceutical company focused on non-opioid, biologic-based pain therapies and its merger with MindWave Innovations Inc., an institutional Digital Asset Treasury solutions provider.
Among the most informative documents are the company’s current reports on Form 8-K, which describe material events such as the entry into an Agreement and Plan of Merger with MindWave Innovations Inc., Apimeds Merger Sub, Inc., and Lokahi Therapeutics, Inc.; the structure of the merger consideration, including common and preferred stock; and the resulting ownership percentages. Other 8-K filings detail amendments to bylaws to allow shareholder action by written consent, changes to executive employment agreements, and departures or removals of directors, along with the composition of the remaining board.
Filings also address capital structure and financing arrangements, including a Securities Purchase Agreement for senior convertible notes, amendments to that agreement, and a certificate of designation for Series A Convertible Preferred Stock. An amended Form 8-K (8-K/A) explains corrections to the merger agreement and to the number of preferred shares designated, illustrating how Apimeds uses SEC filings to clarify and update previously reported terms.
Investors reviewing APUS filings can trace the company’s initial public offering on the NYSE American, its status as an emerging growth company, and subsequent PIPE financing associated with the MindWave merger, as described across registration statements and current reports. The filings also reference the preparation of an Information Statement under Section 14(c) of the Exchange Act to describe the merger, related stockholder approvals, reverse stock split, and equity incentive plan changes.
On Stock Titan, these SEC documents are supplemented by AI-powered summaries that highlight the main points of lengthy filings, such as 8-Ks and related exhibits. Users can quickly understand how each filing relates to Apimeds’ Apitox development program, its non-opioid pain-management focus, its integration of digital-asset treasury capabilities, and its governance and capital structure decisions, without reading every page in full.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a routine insider equity grant. The company’s Chief Executive Officer and Director received a stock option to purchase 215,000 shares at an exercise price of $1.92 on 10/15/2025. The option vests in quarterly installments beginning October 1, 2025 and is fully vested after three years, with full vesting upon a Change in Control. It is not exercisable until stockholders approve an amendment to the incentive plan to increase available shares. The option expires on 10/15/2035.
Apimeds Pharmaceuticals US, Inc. reported a corporate governance change. On October 15, 2025, the board amended the company’s bylaws to allow shareholder action by written consent, enabling stockholders to take certain actions without a meeting when the required consents are obtained.
The full text of the amendment is provided as Exhibit 3.1 to the report.
Apimeds Pharmaceuticals US, Inc. reported interim results showing a May 12, 2025 IPO that sold 3,375,000 shares at $4.00 per share, generating net proceeds of approximately $11.9 million after underwriting discounts, offering expenses and the value of Advisor/Placement Agent warrants. Cash balances plus IPO proceeds are stated to be sufficient to fund operations for at least twelve months from the condensed financial statements issuance date. Shares outstanding increased to 12,575,983 at June 30, 2025 from 7,903,850 at December 31, 2024, reflecting the IPO and conversions of convertible notes. The company recognized stock-based compensation including $1.7 million in fully vested stock grants and stock option expense of $192,053. Advisor and placement agent warrants were recorded as liabilities or reductions to additional paid-in capital with remeasurement activity of $9,518. Convertible notes and promissory notes were amended, converted, or extended, and certain related-party financing activity is disclosed.